6185 — Cansino Biologics Share Price
Last trade - 00:00- HK$7.62bn
- HK$6.36bn
- CNY824.88m
- 30
- 14
- 76
- 32
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 93.39 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.46 | ||
| Price to Tang. Book | 1.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.52% | ||
| Return on Equity | -7.44% | ||
| Operating Margin | -48.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 18.54 | 4,299.7 | 1,031.04 | 345.18 | 824.88 | 1,100.67 | 1,428.4 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +24073 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
Directors
- Xuefeng Yu CHM (57)
- Luo Xi CFO (44)
- Shou Bai Chao COO (58)
- Dongxu Qiu EVP (61)
- Huihua Mao EVP (59)
- Zhu Tao CSO (48)
- Wang Jing DGM (41)
- Ming King Chiu SEC (44)
- Jin Cui SEC (34)
- Wing-Yu Leung NED (51)
- Liang Lin NED (46)
- Xiao Zhi NED (42)
- Shuifa Gui NID (56)
- Jianzhong Liu NID (57)
- Shiu Kwan Wai NID (57)
- Zhu Xin NID (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 13th, 2009
- Public Since
- March 28th, 2019
- No. of Employees
- 1,105
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 247,449,899
- Address
- West District Biomedical Park, No. 185, TIANJIN, 300457
- Web
- https://www.cansinotech.com/
- Phone
- +86 2258213766
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for 6185
Similar to 6185
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:45 UTC, shares in Cansino Biologics are trading at HK$30.80. This share price information is delayed by 15 minutes.
Shares in Cansino Biologics last closed at HK$30.80 and the price had moved by +67.76% over the past 365 days. In terms of relative price strength the Cansino Biologics share price has outperformed the FTSE Developed Asia Pacific Index by +69.67% over the past year.
The overall consensus recommendation for Cansino Biologics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCansino Biologics does not currently pay a dividend.
Cansino Biologics does not currently pay a dividend.
Cansino Biologics does not currently pay a dividend.
To buy shares in Cansino Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$30.80, shares in Cansino Biologics had a market capitalisation of HK$7.62bn.
Here are the trading details for Cansino Biologics:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6185
Based on an overall assessment of its quality, value and momentum Cansino Biologics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cansino Biologics is HK$42.20. That is 37% above the last closing price of HK$30.80.
Analysts covering Cansino Biologics currently have a consensus Earnings Per Share (EPS) forecast of CNY0.00 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cansino Biologics. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +25.52%.
As of the last closing price of HK$30.80, shares in Cansino Biologics were trading +13.33% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cansino Biologics PE ratio based on its reported earnings over the past 12 months is 93.39. The shares last closed at HK$30.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cansino Biologics' management team is headed by:
- Xuefeng Yu - CHM
- Luo Xi - CFO
- Shou Bai Chao - COO
- Dongxu Qiu - EVP
- Huihua Mao - EVP
- Zhu Tao - CSO
- Wang Jing - DGM
- Ming King Chiu - SEC
- Jin Cui - SEC
- Wing-Yu Leung - NED
- Liang Lin - NED
- Xiao Zhi - NED
- Shuifa Gui - NID
- Jianzhong Liu - NID
- Shiu Kwan Wai - NID
- Zhu Xin - NID